Tag - AXGN

Developments

AxoGen completes target enrollment in Phase 3 nerve graft study

AxoGen (NASDAQ:AXGN) completed target enrollment of 220 subjects in its Phase 3 RECON study evaluating its Avance nerve graft in digital nerve injuries. The study will compare AxoGen’s Avance nerve graft with...

July 22, 2020

Markets

WB cuts AxoGen to MP from OP

William Blair downgraded AxoGen (NASDAQ:AXGN) to “market perform” from “outperform” after the company reduced revenue guidance for 2019. The stock closed at $17.58 on Aug. 6, near the low end of its 52-week range of $14...

August 7, 2019

Tag - AXGN

AxoGen completes target enrollment in Phase 3 nerve graft study

WB cuts AxoGen to MP from OP

General

More